SCHEDULE: FMR LLC Reports 8.1% Stake in Bio-Techne Corp

FMR LLC and Abigail P. Johnson have updated their Schedule 13G filing to reflect beneficial ownership of 8.1% of Bio-Techne Corp's common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Bio-Techne Corp's common stock.
• As of June 30, 2026, FMR LLC beneficially owns 12,754,783.64 shares, representing 8.1% of the class of securities.
• Abigail P. Johnson, a Director, Chairman, and CEO of FMR LLC, is also listed as a reporting person.
• The filing indicates that FMR LLC and its subsidiaries, along with other entities like FIAM LLC, Fidelity Diversifying Solutions LLC, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, and Strategic Advisers LLC, are involved in this beneficial ownership.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports a change in beneficial ownership percentage and does not contain operational or financial performance updates.

Positives

• FMR LLC's continued investment in Bio-Techne Corp may signal confidence in the company's long-term prospects.
• The filing clarifies the ownership structure and reporting responsibilities among FMR LLC and its affiliates.

Negatives

• The filing does not provide any new financial performance data or operational updates for Bio-Techne Corp.

Risks

• While FMR LLC states the shares are held in the ordinary course of business, significant ownership by a large investment firm can still influence market perception and trading dynamics.
• The filing does not detail specific reasons for the reported ownership percentage, leaving potential strategic intentions open to interpretation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Bio-Techne Corp's future performance.

Management Comments

• FMR LLC: 'This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters").'
• FMR LLC: 'The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.'

Industry Context

StockSavvy.ai notes that significant institutional ownership, as reported in this Schedule 13G, is common in the biotechnology sector. Changes in beneficial ownership percentages by large asset managers like FMR LLC can sometimes precede or coincide with shifts in company strategy or market performance, though this filing itself does not indicate such changes.

Comparison to Industry Standards

• As a Schedule 13G filing, it adheres to SEC regulations for reporting beneficial ownership exceeding 5% of a class of securities.
• The reporting of 8.1% ownership by FMR LLC is within the typical range for institutional investors in the biotechnology sector, which often hold substantial stakes in companies like Bio-Techne Corp.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional investor's stake, which can influence market perception. However, it does not directly impact shareholder rights or immediate value.
• Management: The filing confirms FMR LLC's substantial investment, which may be viewed positively by management as a sign of support, but also implies increased scrutiny.
• Creditors: No direct impact is indicated as the filing pertains to equity ownership.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to report any material changes in their beneficial ownership of Bio-Techne Corp's common stock as required by SEC regulations.

Key Dates

Keywords

Bio-Techne Corp, FMR LLC, Schedule 13G, Beneficial Ownership, Investment Management, Securities Ownership, Abigail P. Johnson